Andra AP fonden Has $15.26 Million Stake in Illumina, Inc. $ILMN

Andra AP fonden increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 56.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 160,700 shares of the life sciences company’s stock after purchasing an additional 58,209 shares during the quarter. Andra AP fonden’s holdings in Illumina were worth $15,262,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC boosted its position in Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after buying an additional 1,174,295 shares during the last quarter. Edmond DE Rothschild Holding S.A. boosted its holdings in Illumina by 140.1% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after acquiring an additional 833,750 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Illumina by 1,558.0% in the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock worth $69,528,000 after purchasing an additional 684,802 shares during the period. Pacer Advisors Inc. acquired a new stake in Illumina in the third quarter worth about $61,663,000. Finally, Invesco Ltd. raised its holdings in Illumina by 48.9% during the 2nd quarter. Invesco Ltd. now owns 1,353,077 shares of the life sciences company’s stock worth $129,097,000 after purchasing an additional 444,543 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Launched TruPath Genome and unveiled a NovaSeq X roadmap at AGBT — new product roadmap and platform upgrades can drive future instrument sales and recurring consumable revenue, and management highlighted multiomics/cancer initiatives that improve long‑term growth visibility. Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
• Positive Sentiment: Illumina Laboratory Services to provide clinical whole‑genome sequencing and interpretation to Florida State University’s pediatric rare disease lab — expands clinical lab services, supports adoption of clinical WGS, and helps generate recurring service revenue. Illumina whole‑genome sequencing technology to accelerate rare disease testing in Florida
• Positive Sentiment: Collaboration with Takara Bio on a single‑cell spatial transcriptomics workflow presented at AGBT — strengthens Illumina’s single‑cell and spatial offerings and complements the company’s multiomics strategy. Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow
• Positive Sentiment: Market/flow-driven momentum: analysts and quant flows have turned more constructive after Illumina’s upbeat 2026 outlook and the completed SomaLogic deal — higher relative strength and above‑average volume are cited as drivers of today’s rally. Illumina jumps 5.5% as momentum builds after upbeat outlook and multiomics push
• Neutral Sentiment: Canaccord reiterated a Hold, noting competitive pressures but that 2026 revenue targets remain intact — keeps near‑term expectations cautious despite longer‑term roadmap. Illumina: Competitive Pressures Mounting but 2026 Revenue Targets Still Intact, Justifying a Hold Rating
• Neutral Sentiment: Competitive context: comparisons to fast‑growing peers (e.g., Tempus) highlight execution risk and the need for Illumina to convert product and multiomics momentum into sustained top‑line growth. TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?
• Neutral Sentiment: Short‑interest data released today shows zero reported short shares (likely a reporting anomaly) and thus offers no clear bearish pressure signal at present.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This trade represents a 1.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total value of $275,346.60. Following the completion of the transaction, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The SEC filing for this sale provides additional information. 2.60% of the stock is owned by insiders.

Illumina Stock Up 5.5%

Shares of Illumina stock opened at $134.46 on Friday. The firm has a market cap of $20.56 billion, a PE ratio of 24.67, a P/E/G ratio of 2.44 and a beta of 1.45. The business’s 50 day simple moving average is $135.12 and its 200 day simple moving average is $118.11. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $155.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period last year, the business earned $0.95 EPS. The business’s quarterly revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Barclays raised their target price on shares of Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Wednesday, January 7th. Robert W. Baird set a $137.00 target price on shares of Illumina in a research report on Friday, February 6th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research note on Monday, January 26th. Finally, Stifel Nicolaus lifted their price objective on Illumina from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Six equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus target price of $129.69.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.